New method to measure antibody drugs in breast cancer without invasive sampling
Solid Phase Microextraction as a New Tool for Quantifying Antibody Drugs in Breast Cancer and Building PK-PD models
['FUNDING_R15'] · ALBANY COLLEGE OF PHARMACY · NIH-10795128
This study is testing a new, less invasive way to measure how much of a cancer-fighting drug is in breast cancer tumors, so patients won't need to go through blood draws or biopsies, making it easier and safer to track their treatment.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBANY COLLEGE OF PHARMACY (nih funded) |
| Locations | 1 site (ALBANY, UNITED STATES) |
| Trial ID | NIH-10795128 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel technique called solid phase microextraction to measure therapeutic antibody concentrations directly in breast cancer tumors without the need for invasive procedures like blood draws or biopsies. By using innovative microsampling approaches, the study aims to create a more ethical and less risky way to monitor drug levels, which could lead to better treatment outcomes. The methodology seeks to provide real-time data on drug distribution and effectiveness, potentially transforming how breast cancer therapies are monitored and adjusted. This approach addresses significant challenges in pharmacokinetics and pharmacodynamics, particularly for difficult-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer who are undergoing treatment with antibody drugs.
Not a fit: Patients who are not receiving antibody drug therapies or those with non-breast cancer diagnoses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective monitoring of antibody drug therapies for breast cancer patients.
How similar studies have performed: While the approach of microsampling is innovative, similar techniques in drug monitoring have shown promise in other areas, suggesting potential for success in this novel application.
Where this research is happening
ALBANY, UNITED STATES
- ALBANY COLLEGE OF PHARMACY — ALBANY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MUSTEATA, FLORIN MARCEL — ALBANY COLLEGE OF PHARMACY
- Study coordinator: MUSTEATA, FLORIN MARCEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers